Novavax received a $125 million milestone payment after Sanofi initiated its Phase 3 trial for a combined influenza and COVID-19 vaccine using Novavax's Nuvaxovid and Sanofi's high-dose flu vaccine. The trial targets adults aged 60 and older in Europe to assess safety and immune response. This partnership has already generated over $1 billion in revenue for Novavax, with potential future milestones and royalties tied to manufacturing and U.S. market launch. The collaboration highlights significant market potential in combination vaccines for flu and COVID-19.
Novavax shares trade at USD 10.41 on Pluang as of Oct 29, 2026 20:51 WIB, showing a 0.92% gain for the day. The stock's market cap stands at $1.70 billion with a 52-week range between $6.22 and $12.82. Investor interest remains strong, with 99% of Pluang orders being buys, reflecting confidence in Novavax's ongoing vaccine developments.
